ATE310807T1 - Trennung eines humanen retrovirus - Google Patents
Trennung eines humanen retrovirusInfo
- Publication number
- ATE310807T1 ATE310807T1 AT00939883T AT00939883T ATE310807T1 AT E310807 T1 ATE310807 T1 AT E310807T1 AT 00939883 T AT00939883 T AT 00939883T AT 00939883 T AT00939883 T AT 00939883T AT E310807 T1 ATE310807 T1 AT E310807T1
- Authority
- AT
- Austria
- Prior art keywords
- spumavirus
- present
- human
- separation
- isolated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/17011—Spumavirus, e.g. chimpanzee foamy virus
- C12N2740/17021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/17011—Spumavirus, e.g. chimpanzee foamy virus
- C12N2740/17022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/17011—Spumavirus, e.g. chimpanzee foamy virus
- C12N2740/17041—Use of virus, viral particle or viral elements as a vector
- C12N2740/17043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13921999P | 1999-06-14 | 1999-06-14 | |
PCT/US2000/016433 WO2000077177A2 (en) | 1999-06-14 | 2000-06-14 | Isolation of a human retrovirus |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE310807T1 true ATE310807T1 (de) | 2005-12-15 |
Family
ID=22485625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00939883T ATE310807T1 (de) | 1999-06-14 | 2000-06-14 | Trennung eines humanen retrovirus |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1185628B1 (de) |
AT (1) | ATE310807T1 (de) |
AU (1) | AU5489500A (de) |
DE (1) | DE60024259T2 (de) |
WO (1) | WO2000077177A2 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6492165B1 (en) | 1997-02-12 | 2002-12-10 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Retrovirus isolated from humans |
WO2000024876A2 (en) | 1998-10-27 | 2000-05-04 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Spumavirus isolated from humans |
US6441114B1 (en) | 1999-06-11 | 2002-08-27 | 3M Innovative Properties Company | Adhesives for use on fluorine-containing or polycarbonate surfaces |
US6800475B1 (en) | 1999-06-14 | 2004-10-05 | The United States Of America As Represented By The Department Of Health And Human Services | Isolation of a human retrovirus |
CA3092891A1 (en) | 2018-04-27 | 2019-10-31 | Mayo Foundation For Medical Education And Research | Foamy viruses and methods of use |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5882912A (en) * | 1997-02-12 | 1999-03-16 | Center For Disease Control And Prevention | Retrovirus isolated from humans |
-
2000
- 2000-06-14 AU AU54895/00A patent/AU5489500A/en not_active Abandoned
- 2000-06-14 DE DE60024259T patent/DE60024259T2/de not_active Expired - Lifetime
- 2000-06-14 AT AT00939883T patent/ATE310807T1/de active
- 2000-06-14 EP EP00939883A patent/EP1185628B1/de not_active Expired - Lifetime
- 2000-06-14 WO PCT/US2000/016433 patent/WO2000077177A2/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP1185628B1 (de) | 2005-11-23 |
WO2000077177A3 (en) | 2001-08-23 |
DE60024259D1 (de) | 2005-12-29 |
AU5489500A (en) | 2001-01-02 |
WO2000077177A2 (en) | 2000-12-21 |
EP1185628A2 (de) | 2002-03-13 |
DE60024259T2 (de) | 2006-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hörner et al. | A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine | |
Beljanski et al. | Enhanced influenza virus-like particle vaccination with a structurally optimized RIG-I agonist as adjuvant | |
Masopust et al. | Dynamic T cell migration program provides resident memory within intestinal epithelium | |
ATE314095T1 (de) | Virusähnliche partikel zur induktion von autoantikörpern | |
Webby et al. | Protection and compensation in the influenza virus-specific CD8+ T cell response | |
RU2432358C2 (ru) | Способ уничтожения злокачественной клетки | |
Chandler et al. | Immunomodulatory effects of hydroxychloroquine and chloroquine in viral infections and their potential application in retinal gene therapy | |
FR11C0027I2 (fr) | Virus de l'influenza recombinants pour vaccins et traitement genetique | |
EA200400376A1 (ru) | Пептиды, полученные из казеина, и их использование в терапии | |
SG156652A1 (en) | Yeast-based therapeutic for chronic hepatitis c infection | |
KR102195196B1 (ko) | 종양원성 바이러스성 폴리펩티드 양성 종양 치료용 폴리뉴클레오티드 | |
CN107073089A (zh) | 用于癌症疫苗的包被的溶瘤腺病毒 | |
CN103386128B (zh) | 一种含联合佐剂的结核亚单位疫苗 | |
MX2009008118A (es) | Polipeptido e2 del virus del papiloma usado para vacunacion. | |
BRPI0816134A2 (pt) | Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença. | |
EA200100302A1 (ru) | Способы и композиции для протективной и терапевтической генетической иммунизации | |
Banihashemi et al. | Safety and efficacy of combined intramuscular/intranasal RAZI-COV PARS vaccine candidate against SARS-CoV-2: a preclinical study in several animal models | |
Janelle et al. | Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy | |
Ellerhoff et al. | Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus | |
Kennedy et al. | A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model | |
GB2429711A (en) | Heart and skeletal muscle inflammation (HSMI) virus | |
ATE310807T1 (de) | Trennung eines humanen retrovirus | |
Takeda et al. | Enhanced susceptibility of B lymphoma cells to measles virus by E pstein–B arr virus type III latency that upregulates CD 150/signaling lymphocytic activation molecule | |
Kos et al. | Induction of primary anti‐viral cytotoxic T cells by in vitro stimulation with short synthetic peptide and interleukin‐7 | |
DE69633919D1 (de) | Mehrzweckvakzine gegen umhüllte viren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1185628 Country of ref document: EP |